Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ: EDIT )

1.210 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday! 
Via InvestorPlace
NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Is Editas Stock a Buy Now?
Shares of the gene-editing company are close to their 52-week lows. Does it make sense to buy the stock now? 
Via The Motley Fool
Expert Ratings for Editas Medicine
Via Benzinga
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 9/29
Via Investor Brand Network
Analyst Expectations for Editas Medicine's Future
Via Benzinga
Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things
It's key to understand the resources it will take to deliver a company's pipeline. 
Via The Motley Fool
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
The better of the pair should be able to beat Bluebird Bio. 
Via The Motley Fool
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors. 
Via Benzinga
Expert Ratings for Editas Medicine
Via Benzinga
Is Editas Medicine Stock a Buy Now?
The fortunes of this once-promising biotech company have changed in the past year. 
Via The Motley Fool
Why Editas Medicine Stock Is Soaring Today
Investors are cheering a big analyst upgrade for the gene-editing stock. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
Via Benzinga
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market... 
Via Benzinga
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Gene Editing Stock to Buy Now, and 1 to Sell
Target markets matter. So does having the cash to get to them. 
Via The Motley Fool
Editas Medicine Announces Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
Is the Street's optimism justified here? 
Via The Motley Fool
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
From Editas Medicine, Inc.
Via GlobeNewswire
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
Reaching profitability could be harder than investors expect. 
Via The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.